AbbVie Agrees to Acquire Apogee Therapeutics in $10.9 Billion Deal
AbbVie (ABBV) has agreed to acquire Apogee Therapeutics (APGE) for $135.11 per share, or approximately $10.9 billion total equity value. The all-cash deal will add Apogee's clinical-stage treatments targeting inflammatory and immunological diseases to AbbVie’s pipeline.
Topics: clinical-stage_treatments inflammatory_diseases pharmaceuticals